Dr BOISBRUN Michel

Fiche personne

Coordonnées

Université de Lorraine, CNRS, L2CM
54000 NANCY

03 83 68 43 63

Territoire

Lorraine

Statut

Enseignant-Chercheur

Affiliation

Université de Lorraine (UL)

Équipes/plateformes

Equipe Laboratoire Lorrain de Chimie Moléculaire (L2CM) - UMR 7053

Recherche

Expertises :
- Recherche:Chimie

Projets

Intercalants induits par la lumière

2023 - Porteur du projet : Dr BOISBRUN Michel

Identification de cibles cellulaires potentielles de nouvelles thiazolidine-2,4-diones à activité antiproliférative

2016 - Porteur du projet : Dr MAZERBOURG Sabine - Partenaire : Dr BOIREAU Wilfrid , Dr BOISBRUN Michel , Mme MAES Pauline

Publications

Synthesis and Pharmacological Characterization of Fluorescent Ligands Targeting the Angiotensin II Receptors Derived from Agonists, β-Arrestin-Biased Agonists, and Antagonists.

Delaitre C, Boisbrun M, Acherar S, Dias A, Kleinclauss A, Achard M, Colin M, Nguyen TM, Humbert N, Chmeis K, Martinez KL, Gilles N, Robin P, Lecat S, Dupuis F

J Med Chem. 2024 11 11;:

The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitors

Muller C, Lacroix-Malgras V, Kluza J, Laine W, Güler Y, Bost F, Boisbrun M, Mazerbourg S, Flament S

Cancer Cell Int. 2024 04 10;24(1):132

Unexplored Vinylic-Substituted 5-Benzylidenethiazolidine-2,4-diones: Synthesis and DFT/NMR Stereochemical Assignment.

Dupommier D, Boisbrun M, Monard G, Comoy C

J Org Chem. 2023 02 27;:

Characterization of Biological Properties of Individual Phenolamides and Phenolamide-Enriched Leaf Tomato Extracts.

Roumani M, Ropars A, Robin C, Duval RE, Frippiat JP, Boisbrun M, Larbat R

Molecules. 2023 02 6;28(4):

Photoisomerization of Arylidene Heterocycles: Toward the Formation of Fused Heterocyclic Quinolines.

Cortelazzo-Polisini E, Boisbrun M, Gansmüller AH, Comoy C

J Org Chem. 2022 07 8;:

AB186 Inhibits Migration of Triple-Negative Breast Cancer Cells and Interacts with α-Tubulin.

Geoffroy M, Lemesle M, Kleinclauss A, Mazerbourg S, Batista L, Barberi-Heyob M, Bastogne T, Boireau W, Rouleau A, Dupommier D, Boisbrun M, Comoy C, Flament S, Grillier-Vuissoz I, Kuntz S

Int J Mol Sci. 2022 06 20;23(12):

Transcriptomics and Metabolomics Analyses Reveal High Induction of the Phenolamide Pathway in Tomato Plants Attacked by the Leafminer .

Roumani M, Le Bot J, Boisbrun M, Magot F, Péré A, Robin C, Hilliou F, Larbat R

Metabolites. 2022 05 26;12(6):

Targeting the Angiotensin II Type 1 Receptor in Cerebrovascular Diseases: Biased Signaling Raises New Hopes.

Delaitre C, Boisbrun M, Lecat S, Dupuis F

Int J Mol Sci. 2021 Jun 23;22(13):

New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.

Dupommier D, Muller C, Comoy C, Mazerbourg S, Bordessa A, Piquard E, Pawlak M, Piquard F, Martin H, De Fays E, Grandemange S, Flament S, Boisbrun M

Eur J Med Chem. 2019 Dec 4;187:111939

Synthesis and Antibacterial Evaluation of Bis-thiazolium, Bis-imidazolium, and Bis-triazolium Derivatives.

Thomas B, Duval RE, Fontanay S, Varbanov M, Boisbrun M

ChemMedChem. 2019 May 22;:

Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor.

Meyer M, Foulquier S, Dupuis F, Flament S, Grimaud L, Henrion D, Lartaud I, Monard G, Grillier-Vuissoz I, Boisbrun M

Eur J Med Chem. 2018 Aug 31;158:334-352

Biotinylation enhances the anticancer effects of 15d‑PGJ2 against breast cancer cells.

Colin C, Meyer M, Cerella C, Kleinclauss A, Monard G, Boisbrun M, Diederich M, Flament S, Grillier-Vuissoz I, Kuntz S

Int. J. Oncol.. 2018 Mar 28;:

Pro-apoptotic effect of Δ2-TGZ in "claudin-1-low" triple-negative breast cancer cells: involvement of claudin-1.

Geoffroy M, Kleinclauss A, Grandemange S, Hupont S, Boisbrun M, Flament S, Grillier-Vuissoz I, Kuntz S

Breast Cancer Res. Treat.. 2017 Jul;:

Δ2-Troglitazone promotes cytostatic rather than pro-apoptotic effects in breast cancer cells cultured in high serum conditions.

Berthe A, Flament S, Grandemange S, Zaffino M, Boisbrun M, Mazerbourg S

Cell Cycle. 2016 Dec;15(24):3402-3412

Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?

Mazerbourg S, Kuntz S, Grillier-Vuissoz I, Berthe A, Geoffroy M, Flament S, Bordessa A, Boisbrun M

Curr Top Med Chem. 2016 ;16(19):2115-24

Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and thiazolidinediones.

Kuntz S, Mazerbourg S, Boisbrun M, Cerella C, Diederich M, Grillier-Vuissoz I, Flament S

Biochem Pharmacol. 2014 Nov 1;92(1):102-11

Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.

Bordessa A, Colin-Cassin C, Grillier-Vuissoz I, Kuntz S, Mazerbourg S, Husson G, Vo M, Flament S, Martin H, Chapleur Y, Boisbrun M

Eur J Med Chem. 2014 Aug 18;83:129-40

Synthesis and Anti-Proliferative Activity of New Biphenyle-Benzylidenethiazolidine-2,4-dione Bis-Adducts Containing Various Heterocyclic Cores.

Meyer M, Kuntz S, Grillier-Vuissoz I, Martin H, Richert L, Flament S, Chapleur Y, Boisbrun M

Lett Drug Des Discov. 2014 Mar;11(3):256-64.

Voir plus

Fiche personne Projets Publications

Retrouvez aussi

Unités de recherche, établissements

Projets de recherche

Publications scientifiques